Immunotherapy and Tumor Microenvironment in HIV/AIDS Cancer Patients

HIV/艾滋病癌症患者的免疫治疗和肿瘤微环境

• 批准号: 10249752
• 负责人: ROBERT H VONDERHEIDE
• 金额: $ 7.34万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-12-01 至 2020-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10249752
• 关键词: AIDS/HIV problem; Address; Adoptive Immunotherapy; African; Basic Science; Behavior; Biology; Cancer Biology; Cancer Burden; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Patient; Catchment Area; Cause of Death; Clinical; Clinical Research; Clinical Sciences; Communities; Complex; County; Cutaneous; Delaware; Detection; Diagnosis; Education and Outreach; Environmental Impact; Fostering; Genetic; Genomics; Goals; Grant; Health; Immunotherapy; Informatics; Infusion procedures; Lead; Leadership; Malignant Neoplasms; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of lung; Mesothelioma; Molecular; Molecular Epidemiology of Cancer; New Jersey; Obesity; Patients; Pediatric Hospitals; Pennsylvania; Philadelphia; Population Research; Population Sciences; Positioning Attribute; Prevention; Research; Resistance; Resources; Scientist; Skin tanning; Smoking; Statutes and Laws; Sun Exposure; Toxic Environmental Substances; Toxicology; Translations; United States; Universities; University Hospitals; behavior change; brain behavior; cancer care; cancer epidemiology; cancer therapy; cancer type; checkpoint therapy; clinical practice; cognitive neuroscience; environmental carcinogenesis; epigenomics; ethnic diversity; innovation; malignant breast neoplasm; melanoma; member; molecular imaging; novel; outreach program; patient oriented; personalized diagnostics; personalized medicine; precision oncology; prevent; programs; rare cancer; recruit; targeted treatment; therapy development; therapy resistant; tool; trait; tumor; tumor metabolism; tumor microenvironment; vaccine development; AIDS/HIV problem; Address; Adoptive Immunotherapy; African; Basic Science; Behavior; Biology; Cancer Biology; Cancer Burden; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Patient; Catchment Area; Cause of Death; Clinical; Clinical Research; Clinical Sciences; Communities; Complex; County; Cutaneous; Delaware; Detection; Diagnosis; Education and Outreach; Environmental Impact; Fostering; Genetic; Genomics; Goals; Grant; Health; Immunotherapy; Informatics; Infusion procedures; Lead; Leadership; Malignant Neoplasms; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of lung; Mesothelioma; Molecular; Molecular Epidemiology of Cancer; New Jersey; Obesity; Patients; Pediatric Hospitals; Pennsylvania; Philadelphia; Population Research; Population Sciences; Positioning Attribute; Prevention; Research; Resistance; Resources; Scientist; Skin tanning; Smoking; Statutes and Laws; Sun Exposure; Toxic Environmental Substances; Toxicology; Translations; United States; Universities; University Hospitals; behavior change; brain behavior; cancer care; cancer epidemiology; cancer therapy; cancer type; checkpoint therapy; clinical practice; cognitive neuroscience; environmental carcinogenesis; epigenomics; ethnic diversity; innovation; malignant breast neoplasm; melanoma; member; molecular imaging; novel; outreach program; patient oriented; personalized diagnostics; personalized medicine; precision oncology; prevent; programs; rare cancer; recruit; targeted treatment; therapy development; therapy resistant; tool; trait; tumor; tumor metabolism; tumor microenvironment; vaccine development

The goal of the Abramson Cancer Center (ACC) of the University of Pennsylvania is to bring together more than 310 members to transform the paradigm of patient-centered cancer care and cancer control by integrating high impact Programs of basic, clinical, and population-based research, fostering pioneering scientific discoveries, and facilitating the translation of these discoveries into clinical practice. In doing so, the ACC builds upon the great clinical cancer care at renowned hospitals of the University of Pennsylvania and the Children’s Hospital of the Philadelphia. The ACC continues to build on its significant historical strengths in basic cancer biology, translational immunotherapy, and population science research. By leveraging the infusion of new Institutional resources and significant philanthropic resources, the ACC will continue to innovate to reduce the burden of cancer in our catchment area during the next project period and will seek to: (1) Accelerate and expand its leadership in adoptive cellular immunotherapy, combination immune checkpoint therapies, and vaccine development for both prevention and treatment of cancers. (2) Increase translation of cancer basic biology through the philanthropic and Institutionally supported ACC Translational Centers of Excellence that integrate basic, translational and clinical scientists from the ACC Programs to impact on the prevention, detection, and treatment of specific types of cancers that afflict our catchment area. (3) Accelerate precision cancer medicine through novel Molecular Imaging, the Center for Personalized Diagnostics, the Molecular Tumor Board, and the Circulating Tumor Material Developing Core, which were implemented in the past project period, and the implementation of the Center for Rare Cancers and Personalized Therapy in the next project period. (4) Innovate means to understand, prevent, and treat therapy-resistant cancers by incorporating genomics, epigenomics, informatics and research in cancer metabolism, which is frequently re-wired in resistance to targeted therapies. (5) Lead population-based research through recruitment and research tools in genetics and complex traits with an emphasis on cancer epidemiology. Implement projects in cancer molecular epidemiology among patients of African descent and accelerate our Outreach Program to increase research relevant to our catchment area. (6) Launch a new Brain and Behavior Change initiative and harness new tools from cognitive neurosciences to control cancer by modulating behaviors that predispose to smoking or contribute to obesity. Lead in Toxicology and Environmental Carcinogenesis to understand environmental toxins and impact the health of patients with mesothelioma in our catchment area.

宾夕法尼亚大学艾布拉姆森癌症中心（ACC）的目标是将更多 比310名成员通过整合而改变以患者为中心的癌症护理和癌症控制的范例 基础，临床和基于人群的研究的高影响计划，促进开拓性科学 发现，并支持这些发现转化为临床实践。这样，ACC 建立在宾夕法尼亚大学著名医院和 费城儿童医院。 ACC继续以其重要的历史优势发展 基本的癌症生物学，转化免疫疗法和人群科学研究。通过利用 ACC注入新的机构资源和大量慈善资源，将继续 在下一个项目期间，创新以减少我们集水区的癌症燃烧，并将寻求： （1）加速和扩大其在适应性细胞免疫疗法，联合免疫疗法方面的领导 检查点疗法以及用于预防和治疗癌症的疫苗开发。 （2）通过慈善和机构支持的ACC增加癌症基本生物学的翻译 卓越的转化中心，将ACC的基本，翻译和临床科学家整合在一起 影响折磨我们的特定类型的癌症的预防，检测和治疗的计划 集水区。 （3）通过新颖的分子成像加速精密癌症医学，该中心是个性化的中心 诊断，分子肿瘤板和循环肿瘤材料的发展核心 是在过去的项目期间实施的，以及稀有癌症中心的实施 在下一个项目期间的个性化治疗。 （4）创新的方法是通过合并基因组学来理解，预防和治疗耐治疗的癌症， 癌症代谢的表观基因组学，信息和研究，经常以抵抗力重新连接 靶向疗法。 （5）通过募集遗传学和复杂特征的招募和研究工具的主要研究领导研究 重点是癌症流行病学。在癌症分子流行病学中实施项目 非洲血统的患者并加速了我们的外展计划，以增加与我们的研究相关的研究 集水区。 （6）从认知神经科学发起新的大脑和行为改变计划，并利用新工具 通过调节容易吸烟或有助于肥胖的行为来控制癌症。领导 毒理学和环境致癌作用，以了解环境毒素并影响健康 我们集水区间皮瘤的患者。